AAAAI Posters 2023 Poster 8: A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration of Intranasal ARS-1 (neffy® Nasal Spray) to Pediatric Subjects with a History of Systemic Allergic Reactions Poster 9: Pharmacokinetics of Self-Administration of ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Manual Intramuscular (IM) Epinephrine 0.3 mg by Health Care Provider (HCP) Poster 14: ARS-1 (neffy® Nasal Spray) 2.0 mg Versus Epinephrine Injection Products: An Integrated Pharmacokinetic Analysis Poster 20: Use of Over-the-Counter Products to Treat Severe Allergic Reactions Before an Epinephrine Auto-Injection (EAI) Device: Results of a Patient/Caregiver Survey Poster 28: Epinephrine Auto-Injector Prescriptions Are Not Filled Due to Dislike of Needles: Results of a Patient Survey Product is for Investigational Use; neffy is the proposed trade name, not yet FDA approved, and might change.
